Genes Could Dictate Weight Loss Jab Success

New research indicates that genetic factors may play a role in determining the effectiveness of weight-loss jabs. A study examining data from almost 28,000 individuals identified specific gene variants associated with varying responses to GLP-1 receptor agonists. These variations could partially explain why some people experience significant weight loss while others see minimal benefit.

The study, published in the journal Nature, highlighted two key gene variants. One variant in the GLP1 receptor gene was linked to a greater decrease in BMI for those taking GLP-1 drugs. Another variant in the gastric inhibitory polypeptide receptor gene was associated with nausea and vomiting side effects when taking tirzepatide, though not with weight loss amount.

Academics involved in the study noted that these genetic differences may contribute to individual variability in weight loss outcomes. However, they emphasized that non-genetic factors such as gender, age, and the specific treatment used also significantly influence results. Experts suggest that while genetics plays a part, its effect is modest, and more research is needed before genetic information can guide treatment decisions in routine clinical practice.

This research could pave the way for precision medicine in weight management. Currently, millions in the UK are using weight-loss drugs, with many obtaining them privately due to rationing. The potential for personalized approaches acknowledges the complex interplay of genetics, behavior, and clinical factors in achieving successful weight management outcomes.